Clinical Trials Logo

Macular Degeneration clinical trials

View clinical trials related to Macular Degeneration.

Filter by:

NCT ID: NCT00991666 Completed - Clinical trials for Age-related Macular Degeneration

Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration

Start date: July 2001
Phase: N/A
Study type: Interventional

Several methods have been proposed for the measurement of pulsatile ocular blood flow (POBF). The pneumatic tonometer, which is commercially available, assesses POBF by measurement of intraocular pressure (IOP) changes during the cardiac cycle. The investigators have recently developed a method for the measurement of ocular fundus pulsation, which is based on laser interferometry. In contrast to the Langham system the method is non-contractile and yields a high topographic resolution. Moreover, the pneumatic tonometer assesses the ocular pressure pulse, whereas ocular fundus pulsation is a point measure of the ocular volume pulse. These two parameters are related by the ocular rigidity, which refers to the mechanical properties of the eye coats. Age-related macular degeneration (AMD) is the most common cause of blindness in the industrialized nations. The mechanisms behind this severe eye disease are, however, still obscure. It has been hypothesized that alterations in choroidal blood flow and ocular rigidity may contribute to the development and progression of AMD. However, there is currently little data to confirm this hypothesis. The present study is an attempt to investigate choroidal blood flow and ocular rigidity by employing laser interferometric measurement of fundus pulsation and pneumotonometric measurement of fundus pulsation.

NCT ID: NCT00987129 Terminated - Clinical trials for Age-related Macular Degeneration

Omega 6:Omega 3 Ratio and Progression of Age-related Macular Degeneration (AMD).

Start date: March 2012
Phase: Phase 3
Study type: Observational

Docosahexaenoic acid (DHA) supplementation has been shown to prevent specific age-related changes in the retina through biochemical and functional evaluations, but it is unclear whether increased DHA intake-reflected through elevated DHA+EPA blood levels-can affect the natural history and progression of age-related macular degeneration (AMD). AMD is a disease affecting the macula, the part of the eye containing cone photoreceptors at the center of the visual field. The macula is responsible for vision in most daily functions, including reading, seeing fine details, and colour recognition. Severe AMD can lead to a central scotoma, severely impairing daily functioning. AMD can be divided into two forms: the more severe wet AMD, consisting of proliferation of new blood vessels in the retina, and dry AMD characterized by the development of drusen, a buildup of extracellular material . The investigators are focused on the group with the highest risk of developing the two advanced forms of AMD [wet AMD or central geographic atrophy]: patients with unilateral wet AMD and dry AMD in their other eye. The study will consist of following up a cohort of such subjects and monitoring their visual function in a comprehensive manner. Working in concert with clinical ophthalmologists and basic scientists, the investigators will monitor "DHA+EPA" and "Omega6:Omega3 fatty acid ratio" levels in the blood, inherited predispositions through genetic analysis, lipofuscin (an accumulated waste product) levels & AMD progression via fundus photography, visual acuity, and retinal function via full-field and multifocal electroretinograms. These different factors will be cross-correlated and evaluated to determine how omega-3 fatty acids affect the progression of AMD.

NCT ID: NCT00976235 Completed - Clinical trials for Macular Degeneration

A Long-Term Monitoring Study of the IMT-002 Patients

Start date: June 2006
Phase: N/A
Study type: Interventional

This is a 5-year study of patients implanted with the Implantable Miniature Telescope (IMT by Dr. Isaac Lipshitz) under Protocol IMT-002. All patients implanted with the telescope prosthesis who enrolled in the IMT-002 trial were asked to participate in this study to monitor long-term safety. Patients will undergo examinations at six-month intervals up to a total of 5 years following implantation.

NCT ID: NCT00967213 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration

Start date: August 2006
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP) and fundus autofluorescence (FAF) in patients with neovascular age-related macular degeneration receiving combination of ranibizumab (LucentisTM) and verteporfin (Visudyne®) therapy

NCT ID: NCT00964795 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

Start date: December 2009
Phase: Phase 3
Study type: Interventional

The primary objective is to assess long-term safety and tolerability of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in patients with neovascular AMD.

NCT ID: NCT00963339 Completed - Clinical trials for Age Related Macular Degeneration

Age-Related Macular Degeneration (AMD) - Usability Study

AMD
Start date: September 2009
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the usability of the Foresee Home device with intermediate AMD patients.

NCT ID: NCT00951288 Enrolling by invitation - Clinical trials for Age-Related Macular Degeneration

Effect of Saffron Supplementation on Macular Cone-mediated Function in Age-related Macular Degeneration

safAMD
Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This is a pilot interventional study whose aim is to determine the effect of a dietary supplementation with a Crocus Sativus extract, Saffron, on macular cone-mediated function in patients with early age-related macular degeneration (AMD). Pre-clinical evidence ( Maccarone R, Di Marco S, Bisti S. Saffron supplement maintains morphology and function after exposure to damaging light in mammalian retina. Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1254-61.) indicates the potential effectiveness of Saffron as a retinal neuroprotectant in animal models of retinal degenerative disorders.The macular function will be tested by visual acuity and macular cone-mediated electroretinogram (focal electroretinogram, FERG) according to a standardized technique (see citations).

NCT ID: NCT00950638 Completed - Clinical trials for Age-Related Macular Degeneration

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The objectives of this study are to evaluate the safety and tolerability of ARC1905 intravitreous injection in subjects with geographic atrophy secondary to dry age-related macular degeneration (AMD).

NCT ID: NCT00940407 Completed - Clinical trials for Nonexudative Age-related Macular Degeneration

Toronto and Oak Ridge Photobiomodulation Study for Dry Age Related Macular Degeneration

TORPA
Start date: January 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate clinical outcomes of Photobiomodulation treatment on patients with dry Age Related Macular Degeneration (AMD). Photobiomodulation is the use of non thermal, non laser light of specific wavelengths and energy directly on the eye to improve retinal function and delay AMD progression. This is a prospective 2 center phase 2 clinical pilot study with no placebo group.

NCT ID: NCT00935883 Completed - Clinical trials for Age-Related Macular Degeneration

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

COMPLETE
Start date: July 2009
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.